DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Dabrafenib
Dabrafenib
Successful Chemotherapy Is Possible for Seemingly Inoperable Anaplastic Thyroid Cancer
Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma
Original Research Paper In-Silico FDA-Approved Drug Repurposing to Find
Tafinlar, INN-Dabrafenib
Oncology Drug Shortage Update
MEKINIST (Trametinib) Tablets for Oral Use Are Supplied As 0.5 Mg and 2 Mg Tablets for Oral Administration
First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
MAP Kinase Signaling and Inhibition in Melanoma
Estonian Statistics on Medicines 2016 1/41
Attachment 2. Extract from the Clinical Evaluation Report for Dabrafenib
Corporate Medical Policy Template
Phase II Trial of Nilotinib in Patients with Metastatic Malignant Melanoma Harboring KIT Gene Aberration: a Multicenter Trial of Korean Cancer Study Group (UN10-06)
Supplementary Material For
Cardiotoxicity Quick Reference Guide Reported Anticancer Agents Type of Cardiotoxicity Frequency
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib
BRAF, MET, and Her2 Mutations in Lung Cancer
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib
Top View
Treatment of Melanoma/Renal Cell Carcinoma
A Retrospective Analysis of Dabrafenib And/Or Dabrafenib Plus
Treatment of Melanoma and Breast Cancer
BRAF, MEK and KIT Inhibitors for Melanoma: Adverse Events and Their Management
NHS Borders NHS Borders Education Centre Planning & Performance Borders General Hospital Melrose Roxburghshire TD6 9BD 01896 825545
[email protected]
New Frontiers in Therapy of Peripheral Nerve Sheath Tumors In
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma
Carboplatin Yields Extended Survival in Advanced BRAF Wild-Type Melanoma: Results of a Clinical/Correlative Prospective Phase II Clinical Trial
TAFINLAR and Trametinib, After One Month of Treatment, TAFINLAR Safely and Effectively
1 Title: the BRAF and MEK Inhibitors Dabrafenib and Trametinib
Non-Small Cell Lung Cancer
Dabrafenib and Trametinib
Efficacy of Dabrafenib Plus Trametinib Combination in Patients
DRUG NAME: Dabrafenib
BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma LISA WALTER and LUCIE HEINZERLING
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
Analysis of Treatment with Vemurafenib and Dabrafenib in Patients With
Dual-Specificity Protein Phosphatase DUSP4 Regulates Response to MEK